JP2015527379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527379A5 JP2015527379A5 JP2015530363A JP2015530363A JP2015527379A5 JP 2015527379 A5 JP2015527379 A5 JP 2015527379A5 JP 2015530363 A JP2015530363 A JP 2015530363A JP 2015530363 A JP2015530363 A JP 2015530363A JP 2015527379 A5 JP2015527379 A5 JP 2015527379A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- phenyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- -1 pyridinonyl Chemical group 0.000 claims description 12
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims description 6
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 150000002390 heteroarenes Chemical class 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- ROBFQGPOPSWVSY-UHFFFAOYSA-N (1,1,1-trifluoro-2-methylpropan-2-yl) imidazole-1-carboxylate Chemical compound FC(F)(F)C(C)(C)OC(=O)N1C=CN=C1 ROBFQGPOPSWVSY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FMIPLBRBLOPRFW-UHFFFAOYSA-N 2-piperidin-4-ylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1CCNCC1 FMIPLBRBLOPRFW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12183652 | 2012-09-10 | ||
| EP12183652.2 | 2012-09-10 | ||
| PCT/EP2013/068143 WO2014037327A1 (en) | 2012-09-10 | 2013-09-03 | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527379A JP2015527379A (ja) | 2015-09-17 |
| JP2015527379A5 true JP2015527379A5 (enExample) | 2016-10-20 |
| JP6263789B2 JP6263789B2 (ja) | 2018-01-24 |
Family
ID=47044769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530363A Active JP6263789B2 (ja) | 2012-09-10 | 2013-09-03 | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9469631B2 (enExample) |
| EP (1) | EP2892888B1 (enExample) |
| JP (1) | JP6263789B2 (enExample) |
| WO (1) | WO2014037327A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037327A1 (en) | 2012-09-10 | 2014-03-13 | Boehringer Ingelheim International Gmbh | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5244589B2 (ja) * | 2005-06-27 | 2013-07-24 | エグゼリクシス パテント カンパニー エルエルシー | イミダゾールに基づくｌｘｒモジュレーター |
| AU2007291252A1 (en) * | 2006-08-30 | 2008-03-06 | Inovacia Ab | Pyridine compounds for treating GPR119 related disorders |
| WO2009106561A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| US8258158B2 (en) | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| JP5935154B2 (ja) * | 2011-03-14 | 2016-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド |
| WO2014037327A1 (en) | 2012-09-10 | 2014-03-13 | Boehringer Ingelheim International Gmbh | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof |
-
2013
- 2013-09-03 WO PCT/EP2013/068143 patent/WO2014037327A1/en not_active Ceased
- 2013-09-03 JP JP2015530363A patent/JP6263789B2/ja active Active
- 2013-09-03 EP EP13756472.0A patent/EP2892888B1/en active Active
- 2013-09-03 US US14/426,412 patent/US9469631B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112601750B (zh) | Ptpn11（shp2）抑制剂 | |
| JP2019517487A5 (enExample) | ||
| AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| KR101671761B1 (ko) | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 | |
| JP2012507566A5 (enExample) | ||
| CA3019450A1 (en) | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application | |
| JP2017502994A (ja) | Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物 | |
| JP2009541223A5 (enExample) | ||
| RU2013149174A (ru) | Новое имидазооксазиновое соединение или его соль | |
| RU2004121161A (ru) | Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и их применение | |
| JP2016506369A5 (enExample) | ||
| WO2007049532A1 (ja) | アミノジヒドロチアジン誘導体 | |
| RU2014131065A (ru) | Димерные соединения-агонисты рецептора fgf ( fgfr ), способ их получения и их терапевтическое применение | |
| JP2020527173A5 (enExample) | ||
| RU2007108539A (ru) | Производные 1, 2, 4-триазин-6-она, ингибирующие вич | |
| GB0226724D0 (en) | Therapeutic agents | |
| JP2015537017A5 (enExample) | ||
| JP2014510147A5 (enExample) | ||
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| JP2014509600A5 (enExample) | ||
| WO2018075959A4 (en) | Methods using hdac11 inhibitors | |
| JP2017531677A5 (enExample) | ||
| IL283368B2 (en) | Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound | |
| JP2007517007A5 (enExample) | ||
| JP2015524825A5 (enExample) |